Gut bacteria and immune cells to calm autoimmune uveitis

Intestinal T cells and microbiota as therapeutic targets in autoimmune uveitis

NIH-funded research Cleveland Clinic Lerner Com-Cwru · NIH-11123239

Tests whether changing gut bacteria or giving bacterial metabolites can boost immune-regulating cells and reduce eye inflammation for people with autoimmune uveitis.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionCleveland Clinic Lerner Com-Cwru NIH-funded
Lab location1 site (Cleveland, United States)
Project IDNIH-11123239 on NIH RePORTER

What this research studies

Researchers use a mouse model of autoimmune uveitis to see if altering gut bacteria with antibiotics or giving short-chain fatty acids (the chemicals produced when bacteria digest fiber) increases regulatory T cells that calm inflammation. They will transfer these regulatory T cells into other animals and run lab tests to see if the cells suppress harmful immune responses. The team will also track whether immune cells from the gut move to lymph nodes and the eye and whether those changes lower eye inflammation. The goal is to find gut-based ways to reset immune balance that could point toward future treatments for uveitis.

Who could benefit from this research

Good fit: People with chronic non-infectious autoimmune uveitis who are seeking alternatives to broad anti-inflammatory drugs would be most relevant to the findings of this work.

Not a fit: Patients whose uveitis is caused by infection or who have unrelated eye disease are unlikely to benefit from the approaches studied here.

Why it matters

Potential benefit: If successful, this work could lead to new gut-targeted therapies or metabolite treatments that reduce eye inflammation and help prevent vision loss from autoimmune uveitis.

How similar studies have performed: Previous animal studies have shown that changing gut bacteria or giving short-chain fatty acids can raise regulatory T cells and lessen autoimmune inflammation, though human testing for uveitis remains limited.

Where this research is happening

Cleveland, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Autoimmune Diseases
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.